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ABSTRACT
Objectives: To systematize the clinico-radiological symptoms and course of bisphosphonate-related osteonecrosis of jaw 
bone and to evaluate the diagnostic potential of various radiological techniques to detect mild osteonecrosis in each stage of 
the disease.
Material and Methods: The sample consisted of 22 patients previously diagnosed with extraoral malignant disease. Diagnosis 
was based on a clinical examination in conjunction to digital panoramic radiography and cone beam computed tomography 
(CBCT). Two dentomaxillofacial radiologists reviewed all images.
Results: Twenty patients showed mandibular involvement clinically, while two others had a maxillary involvement. Four 
stages of the disease were proposed based on the clinico-radiological findings. Subclinical cortical and lamina dura thickening 
was detected with only three-dimensional CBCT and periapical images, while ulceration and cortical bone thickening was 
detected only by three-dimensional CBCT. Mixed sclerotic, lytic bone destruction involving alveolar and basal bone with 
or without encroachment on the mandibular canal, pathological mandibular fractures were detected by two-dimensional 
panoramic and three-dimensional CBCT images. Other findings are non healing extraction sockets, periapical radiolucencies, 
osteolysis, sequestra, oroantral fistula, and periosteal new bone formation.
Conclusions: The present study showed that bisphosphonate-related osteonecrosis of jaw bone occurs in four distinct clinico-
radiological stages. For mild cases, panoramic image diagnosis was much less obvious, whereas cone beam computed 
tomography was able to fully characterise the bony lesions and describe their extent and involvement of neighbouring 
structures in all cases. Thus cone beam computed tomography might better contribute to the prevention of bisphosphonate-
related osteonecrosis of jaw bone as well to the disease management.
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INTRODUCTION
The relationship between intravenous bisphosphonate 
administration and jaw bone osteonecrosis was first 
reported in 2003 [1]. It is defined as an area of exposed 
bone in the maxillofacial region for more than eight 
weeks in a patient who was receiving a bisphosphonate 
and had not had radiation therapy to the craniofacial 
region [2]. It is often denoted as bisphosphonate-related 
osteonecrosis of the jaw (BRONJ). This describes a 
spectrum of intraoral symptoms, especially seen in 
cancer patients treated with high levels of intravenous 
bisphosphonates.
Bisphosphonates are non-metabolic synthetic analogues 
of pyrophosphate which have potent inhibitory effects 
on bone resorption [3]. They are the drugs of choice in 
prevention and treatment of bone disorders characterised 
by increased bone resorption, such as Paget’s disease, 
osteoporosis, hypercalcaemia of cancer, multiple 
myeloma and bony metastases [3].
Though there is abundant evidence in the literature of the 
benefit of bisphosphonates therapy, growing evidence 
from several recently published reports show that 
patients treated with bisphosphonates have a potential 
risk of develop necrosis of the jaw bone [4-10].
The diagnosis of BRONJ is currently based on the 
patients’ medical history of bisphosphonate treatment 
and clinical evaluation (pain, bone exposure, purulent 
secretion or swelling). The initial appearance of the 
disease is variable and thus, it often comes to the 
attention of the clinician late, when BRONJ has become 
symptomatic.
The role of imaging in the diagnosis of BRONJ and 
the imaging findings has previously been described in 
the literature [11], but no distinct clinico-radiological 
systematization of the disorder has been reported.
Recently, several cone beam computed tomography 
(CBCT) systems have become available, which are 
specifically designed to image hard tissues in the 
maxillofacial region [14].
This results in new diagnostic possibilities with 
increased diagnostic image quality. With the available 
CBCT systems, high-contrast structures can be 
visualized at very low radiation doses, sometimes as 
low as two panoramic radiographs [15]. Such CBCT 
data might therefore help to define the radiological 
range of appearances of BRONJ.
The purpose of the present study was to systematize 
the clinico-radiological symptoms and course of 
bisphosphonate-related osteonecrosis of jaw bone and 
to create guidelines for the most optimal radiological 
examination methods in each stage of the disease.
MATERIAL AND METHODS
Patient recruitment
A series of 22 subjects (17 males and 5 females, age 
range 54 - 87 years, mean age 69.2 years) with a 
diagnosis of osteonecrosis development in the jaw 
bone(s) were consecutively recruited from the patient 
sample visiting the Department of Paediatric and Special 
Dental Care, School of Dentistry, Oral Pathology and 
Maxillofacial Surgery, Faculty of Medicine, Leuven 
between October 2007 and March 2008. They all had 
undergone a biophosphonate treatment based on a 
previous diagnosis of extraoral malignant disease. All 
patients gave their informed consent to participate in the 
study, in accordance with the ethical regulations of the 
University Hospitals, Catholic University of Leuven.
Nine patients had multiple myeloma, 6 prostate cancer, 
3 breast cancer and 4 renal cell cancer. All patients had 
been treated with either individual intravenous doses of 
zoledronate or pamidronate and were therefore at risk 
for developing BRONJ. The diagnosis of BRONJ was 
confirmed through the clinical evaluation of the exposed 
bone to the oral cavity in addition to the negative history 
of radiotherapy to the head and neck.
The presenting symptoms: the localization of 
the necrosis, the presence of suppuration and the 
association with previous extractions or traumas as 
possible triggering factor for the onset of the lesions 
were documented in all patients.
Radiological examination
As part of a routine clinical examination, a digital 
panoramic radiograph was taken using a Cranex Tome® 
(Soredex, Tuusula, Finland) and the CBCT of the jaws 
was obtained using a SCANORA 3D® CBCT unit 
(Soredex, Tuusula, Finland). The CBCT device uses 
complementary metal-oxide semiconductor (CMOS) 
flat panel/CsI detector and is operated at 85 kV and 13 
mA, with a full jaw scan with a 75 x 145 mm field of 
view for a single 360° rotation.
Primary reconstruction of the data provided 1.0 
mm axial, coronal, and sagittal slices (300 - 500 
slices) as well as the three-dimensional volumetric 
surface renderings. The data set had a voxel size of 
 0.25 x 0.25 x 0.25 mm and consisted of contiguous slices 
with respect to the Z-axis. These were reconstructed 
secondarily to provide a curved planar two-dimensional 
multiplanar reconstruction (MPR) 20 mm thick along 
the arch of the mandible that provides a simulated 
“panoramic” equivalent. Panoramic reconstruction 
at narrower defined “focal trough” limits (such as 
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5 – 10 mm) better depicted the degree of involvement 
and extent of margins in a projection that was still cross-
sectional imaging at 1 mm thick slices, and in 1 mm 
slice increments also provided orthogonal views to the 
panoramic curved planar view. Previous radiographs of 
the patients were also retrieved and correlated with the 
present ones for possible changes.
The radiographs and CBCT images were evaluated by 
two dentomaxillofacial radiologists under standardized 
viewing conditions (40 cm viewing distance, diagnostic 
screen, dimmed room). Calibration was done 
beforehand to reduce the intra- and inter-examiner 
variability regarding the following variables: imaging 
characteristics of the alveolar and basal bone (lytic/
erosive, sclerotic, and mixed), presence of sequestrum, 
cortical discontinuity, periosteal response, involvement 
of vital structures (e.g. the mandibular canal and 
maxillary antrum) and soft tissues involvement. Four 
stages of the disease progression were proposed based 
on the clinico-radiological findings.
RESULTS
Demographic data are presented in Table 1. In 
most patients, the lesions initially occurred after 
dental extraction. The body of the mandible was the 
predominant clinical site of involvement in all the 
patients. Area of necrosis was discovered on the CBCT 
image of the mandible in one of the patients with an 
extensive necrosis of the maxilla.
The staging of the disorder was done based on the 
clinico-radiological findings (Table 2).
The least changes at first presentation were observed 
in patients with radiological evidence of osteosclerosis 
involving the cortical bone, alveolar margin and lamina 
dura but with clinically intact mucosa and no oral 
symptoms or discomfort (stage I). This radiological 
finding was only detected using the periapical 
radiographs and CBCT (Figures 1 and 2).
In stage II, ulceration was located in the posterior/ 
S/Na
Age 
(yrs) Gender
b Underlying 
malignancy Localisation Initiating event Signs and symptoms Bisphosphonate
1 66 M Prostate carcinoma Left body of mandible Tooth extraction Non healing extraction socket Zoledronate
2 71 M Prostate carcinoma Right body of mandible Spontaneous Pain, exposed bone Zoledronate
3 74 M Multiple myeloma Left body of mandible Pain from bone Pain, exposed bone Zoledronate
4 54 M Renal cell carcinoma Left body of mandible Tooth extraction Non healing extraction socket Zoledronate
5 75 M Multiple myloma Left body of mandible Spontaneous Mobile tooth Zoledronate
6 55 M Prostate carcinoma Left body and anterior of mandible Tooth extraction 
Non healing extraction socket
Purulent discharge Zoledronate
7 82 M Prostate carcinoma Left maxilla left body of mandible Tooth extraction 
Exposed bone, oro-antral 
fistula, clinically intact 
mucosa on the mandible
Zoledronate
8 69 M Renal cell carcinoma Right body of mandible Spontaneous Ulceration Zoledronate
9 71 M Renal cell carcinoma Right body of mandible Spontaneous Ulceration Zoledronate
10 70 F Multiple myeloma Cortical plate and lamina dura
No clinical 
manifestation None Zoledronate
11 74 M Multiple myeloma Anterior and left body of mandible Tooth extraction Non healing extraction socket
Zoledronate
Pamidronate
12 73 M Multiple myeloma Right and left body of mandible Tooth extraction Non healing extraction socket Zoledronate
13 71 M Prostate carcinoma Right and left body of mandible Spontaneous Intra oral discharging sinus Zoledronate
14 59 M Multiple myeloma Right body of mandible Tooth extraction Non healing extraction socket Zoledronate
15 57 F Renal cell carcinoma Left body of mandible Tooth extraction Bone exposure Zoledronate
16 56 M Multiple myeloma Left body of mandible Spontaneous Bone exposure ZoledronatePamidronate
17 69 F Breast cancer Right body of mandible Spontaneous Bone exposure Zoledronate
18 87 F Breast cancer Left body of mandible Extraction of mobile tooth #37 Painful and mobile tooth #37 Zoledronate
19 87 M Prostate carcinoma Left body of mandible Pain from tooth #36 Non healing extraction socket Zoledronate
20 62 F Breast cancer Right and left maxilla Spontaneous Bone exposure ZoledronatePamidronate
21 68 M Multiple myeloma Left body of mandible Pain from bone Pain, exposed bone Zoledronate
22 72 M Multiple myeloma Left body of mandible Pain from bone Pain, exposed bone Zoledronate
aS/N = serial numbers.
bM = male; F = female.
Table 1. Patients data
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Table 2. Summary of the clinical and radiologic findings, classified according to different stages and manifestations of the disease
Stage N Clinical presentation Radiological findings
Optimal radiological 
examination method
I 2 None
Generalised thickening of cortical plate and lamina dura, focal area 
of sclerosis extending from cortical plate
Periapical/CBCT
II 2
Discomfort, denuded bone in the 
posterior/lingual mandible
Thickening of cortical plate CBCT
III 14
Pain, denuded bone involving alveolar 
bone
Mixed sclerotic and lytic bone destruction involving alveolar bone 
and basal bone, sequestrum
Panoramic/CBCT
IV 4
Denuded bone involving alveolar 
bone, purulent discharge, numbness, 
oro-antral fistula
Mixed sclerotic and lytic bone destruction involving alveolar and 
basal bone, sequestrum, encroachment on the mandibular canal and 
maxillary antrum, pathologic fracture
Panoramic/CBCT
Figure 1. Periapical radiographs of a 71 years old woman (patient number 10), showing generalized osseous sclerosis 
of uniform thickness involving the cortical plate and lamina dura. A and C radiographs shows the pre-bisphosphonate 
therapy condition of the cortical plates and the lamina dura. B and D radiographs shows thickening of the cortical 
plate and lamina dura after 2 years bisphosphonate therapy. No clinical signs and symptoms were established at this 
initial stage.
Figure 2. A = Axial images of the mandible obtained with Scanora 3D® CBCT unit showing thickening of cortical plate and focal region of 
medullary bone density on the left body of mandible, the overlying mucosa is clinically intact.
B = Two-dimensional multiplanar reconstruction image showing the vertical dimension of the region of osteosclecrosis and the relationship 
with mandibular canal.
B
D
A
C
B
A
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lingual mandible in the area of the mylohyoid ridge, the 
exposed bone surface was smooth and patients presented 
with discomfort as the tongue constantly rub on the 
ulceration. Thickening of the cortical plate in the affected 
region was the only radiological findings on CBCT.
Panoramic radiographs did not yield obvious evidence 
of the disease status in stage I and II of the disease 
(Table 2).
Increases in sclerotic manifestations correlated with a 
more sever expression of BRONJ in stage III and IV 
lesions were detected on both imaging modality, yet 
much more pathologic characteristics and the entire 
lesion extent could be visualized on CBCT (Table 2) 
(Figures 3-5).
Figure 3. A = coronal, B = sagital, C = axial and D = three-dimensional images of the mandible obtained with Scanora 
3D® CBCT unit showing region of extensive necrosis in a 71 years old patient. Centrally, a well demarcated bony 
sequestrum is evident, involving the upper border of the mandibular canal.
Figure 4. A = coronal, B = sagital, C = axial and D = three-dimensional images of the mandible obtained with Scanora 
3D® CBCT unit with region of extensive necrosis and pathological fracture of the mandible.
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Figure 5. A = Panoramic radiograph of an 87 years old woman (patient number 18) with breast cancer treated with zoledronate who 
presented with a painful tooth #37.
B = Panoramic radiograph after 7 months, showing non healing extraction site in the left posterior mandible, absence of bone remodeling 
and sclerotic bone changes of the body of the mandible.
C = Panoramic radiograph after 9 months demonstrates a nonhealing extraction site in the left posterior mandible with progressive sclerosis 
of the left body and angle of the mandible with encroachment on the left mandibular canal.
D = Panoramic radiograph after 19 months with intervening curettage, demonstrates progression of sclerosis to pathologic fracture of the 
mandible.
DISCUSSION
A major limitation of this study is the small sample 
size; however the data presented was representative 
of the various clinico-pathologic manifestation of 
BRONJ. Bisphosphonate-related necrosis of jaw bone 
remains a challenge with respect to diagnosis and 
management. This presents a growing concern for oral 
health care workers since the disorder appears almost 
exclusively in the jaws [4,7,16]. This is because the 
diagnosis is made at the late stage when there is bone 
exposure to the oral cavity. Standard diagnosis based 
on clinico-radiological criteria is still lacking and 
there are no clinico-radiological guidelines for the 
clinicians to follow. Bone exposure often occurred 
spontaneously or after dental extractions or oral trauma 
with progression to sequestration associated with 
purulent discharge and in some cases fistula formation 
[4,8,17]. Most reported cases of necrosis of the jaws 
associated with bisphosphonate use involve the recent 
nitrogen-containing injectable bisphosphonates such as 
pamidronate and zoledronate [1,8,18]. Incidentally, all 
patients in this study were treated with this group of 
bisphosphonates.
The pathogenesis of BRONJ remains unclear however, 
many theories have been proposed by various authors 
[4,6]. Most cases of osteonecrosis in this study occurred 
in the posterior alveolar region of the mandible where 
the cortical bone is thickest. The reason for this has been 
attributed to the high bisphosphonates concentration 
in the region as a result of high drug uptake and high 
bone turnover due to constant mastication. [11,19] This 
condition is said to inhibit osteoclastic activity, thereby 
decreasing bone remodeling and predisposing the bone 
to accumulated micro-damage, potentially causing the 
onset of osteonecrosis.
The most common clinical finding in this series is an 
area of ulcerated mucosa with exposed devitalized 
bone. In all patients with exposed necrotic bone, the 
observed area of ulceration was smaller with wider area 
of underlying bone necrosis as previously reported by 
Bedogni et al. [20]. This makes imaging mandatory in 
assessing the extent of the lesion.
In the patients with least changes, the lesion presented 
as a linear sclerosis of uniform thickness limited to the 
alveolar margin and the lamina dura (Figure 1), while 
a focal area of sclerosis was detected on the CBCT of 
the mandible of the other patient who only had bony 
exposure on the maxilla (Figure 2). Both patients had 
intact oral mucosa and did not present with any oral 
symptoms or discomfort in the sclerotic region.
B
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This mild involvement represents the stage I of the 
disorder. This can easily be detected with periapical 
radiograph since the bone changes are still limited to 
the periapical region. Indeed, active bone resorption 
has been reported to be absent at this early stage [6,10], 
CBCT provided a good view of this early discrete and 
subtle bone changes (Figure 2).
Avoiding invasive procedures and institution of 
preventive measures at this  bone pre-exposure stage 
may delay the clinical progress and possibly provide an 
environment conducive to resolution of the condition.
Patients with stage II of the disease had an area of 
ulceration at the posterior/lingual mandible in the area 
of the mylohyoid ridge with no apparent radiological 
changes on the panoramic view but presents as cortical 
thickening on the CBCT. This region had earlier been 
reported as one of most common site of BRONJ [6]. The 
ulceration might have been due to the pressure effect of 
the tongue on the elevated ridge and the bone reaction 
may still be limited to the periosteum at this stage.
Diagnosis at these vital stages may give room for 
prompt implementation of the preventive measure 
recommended for BRONJ in the literature [4,6,7] and 
adequate follow-up to check the progression of the 
disease.
Panoramic radiograph may not be useful in the diagnosis 
of this early lesssion because of its limited resolution, 
two-dimensional nature with anatomic overlap and 
tomographic effect which may not allow visualization 
of the true extent of the bone defects. The present 
finding correlate well with those earlier described by 
Arce et al. [12].
Patients with a more advanced stage of the disease 
presented with bone exposure to the oral cavity at 
previous tooth extraction sites [8,13]. The exposed bone 
had a grayish discoloration with irregular surface, which 
on probing was asymptomatic and avascular. These 
findings were consistent with avascular osteonecrosis 
and similar to the documented findings in literature 
[1,6,8]. The panoramic radiograph in this group of patient 
showed an area of sclerosis with some radiolucency 
with poorly defined margin. CBCT was able to provide 
detailed information about characteristics and extent of 
the cortical and trabecular bone involvement and the 
proximity of the alteration in the bony architecture to 
vital structure such as mandibular canal (Figure 3).
In most severe cases, Stage IV the CBCT and the 
panoramic radiograph now revealed larger areas of 
osseous sclerosis involving the entire cross-sectional 
area of the jaw in all cases, with sclerotic changes 
encroached on the mandibular canal and the maxillary 
antrum. Devitalized bone with radiodense appearance 
and radiolucent rim (Figure 3) denoting bone 
sequestration were also predominant at this advanced 
stage of the disease (Figures 3 and 4), while pathologic 
fracture of the mandible was observed in two patients 
(Figures 4 and 5). 
In all the patients, necrosis involved the alveolar 
margin and the cortical plate, in line with the findings 
reported by Phal et al. [11]. This suggests that BRONJ 
possibly originates in the cortical or alveolar bone with 
a progression towards the medulla.
CBCT imaging allowed high resolution hard tissue 
diagnosis, and when offering a field of view, covering 
both jaws, affected areas could be easily compared to 
non-affected areas while asymptomatic area can also be 
detected.
Furthermore, the CBCT data could also be considered 
valuable for volumetry which helps to determine the 
extent of the disease. As such it can serve as a guide 
towards management planning. Indeed, cross-sectional 
slices allowed identification of the true extent of 
affected marrow and thus facilitated transfer from the 
three-dimensional images to the surgical topographical 
landmarks and vice versa.
The observed radiological characteristics suggests a 
distinct pattern of occurrence and progress of BRONJ, 
starting from the lamina dura and cortical plate, to 
involve the alveolar bone and then progress to enter 
the medullar bone, and finally the entire cross-sectional 
area of the jaw bone. This sequence is confirmed in 
subjects with image follow-up over time; showing that 
the destructive bone changes were often progressive 
(Figures 1 and 5).
While routine jaw imaging for patients receiving 
bisphosphonate therapy may not be justified, it is 
essential that oral health care providers rule out such 
early bone changes, when a patient at risk presents 
with a need for jaw bone imaging. This may allow for 
early diagnosis, better treatment and prevention of new 
potential case as this can make a significant difference 
in the outcome of the disease.
CONCLUSIONS
The present study showed that bisphosphonate-related 
osteonecrosis of jaw bone occur in four distinct clinico-
radiological stages. For mild cases, panoramic image 
diagnosis was much less obvious. Whereas cone beam 
computed tomography was able to fully characterise the 
bony lesions and describe their extent and involvement 
of neighbouring structures in all cases. Thus cone beam 
computed tomography might better contribute to the 
prevention of bisphosphonate-related osteonecrosis of 
jaw bone as well to disease management.
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